Logo CICANCER
Intranet Colaborate

Old CIC Events

Illuminating the beginning of life 02/12/2021

Illuminating the beginning of life

Melina Schuh — Max Planck Institute for Biophysical Chemistry, Göttingen Germany

Defensa de tesis: Cáncer de mama HER2+: mecanismos de resistencia a tratamientos dirigidos y nuevas dianas terapéuticas. 26/11/2021

Defensa de tesis: Cáncer de mama HER2+: mecanismos de resistencia a tratamientos dirigidos y nuevas dianas terapéuticas.

Lucía Gandullo Sánchez — Centro de Investigación del Cáncer

Intracellular traffic of LAT and its role in T cell activation 25/11/2021

Intracellular traffic of LAT and its role in T cell activation

Claire Hivroz — Institut Curie, [Paris, France]

Defensa de tesis: Diagnóstico de clonalidad de los síndromes linfoproliferativos crónicos de células T y NK 24/11/2021

Defensa de tesis: Diagnóstico de clonalidad de los síndromes linfoproliferativos crónicos de células T y NK

Noemí Muñoz García — Centro de Investigación del Cáncer

High-risk cutaneous squamous cell carcinoma: our contributions to the current understanding and research priorities 18/11/2021

High-risk cutaneous squamous cell carcinoma: our contributions to the current understanding and research priorities

Javier Cañueto Álvarez — Hospital Universitario de Salamanca, IBSAL

Workshop of RiaBio Ibero-American Network on Artificial Intelligence applied to BioData 18/11/2021

Workshop of RiaBio Ibero-American Network on Artificial Intelligence applied to BioData

- — RiaBio

TESIS: Systematic analysis of RHO GTPase pathway alterations in cancer 12/11/2021

TESIS: Systematic analysis of RHO GTPase pathway alterations in cancer

Rubén Caloto, Ph.D. student — Centro de Investigación del Cáncer, laboratorio 2

Insights into KRAS biology to identify novel therapeutic strategies for cancer 11/11/2021

Insights into KRAS biology to identify novel therapeutic strategies for cancer

Chiara Ambrogio — Molecular Biotechnology Center (MBC) / University of Torino [Torino, Italy]

Tumor-specific pathways of therapy resistance in ALK-rearranged lymphoma 04/11/2021

Tumor-specific pathways of therapy resistance in ALK-rearranged lymphoma

Roberto Chiarle — Harvard Medical School [Boston, USA]

Defensa de tesis: Evaluación preclínica de mecanismos de resistencia a fármacos inmunomoduladores en mieloma múltiple 29/10/2021

Defensa de tesis: Evaluación preclínica de mecanismos de resistencia a fármacos inmunomoduladores en mieloma múltiple

Pedro Mogollón Arroyo — Centro de Investigación del Cáncer

Arginine methylation and ubiquitylation crosstalk controls DNA end resection and homologous recombination repair 28/10/2021

Arginine methylation and ubiquitylation crosstalk controls DNA end resection and homologous recombination repair

María Pilar Sánchez-Bailón — Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch [Berlin, Germany]

Insights into the biological determinants of clonal evolution and therapeutic vulnerabilities of del(11q) chronic lymphocytic leukemia 21/10/2021

Insights into the biological determinants of clonal evolution and therapeutic vulnerabilities of del(11q) chronic lymphocytic leukemia

Miguel Quijada Álamo — Centro de Investigación del Cáncer, CIC-IBMCC